Elsevier

Ophthalmology

Volume 102, Issue 10, October 1995, Pages 1417-1424
Ophthalmology

Inhibition of Experimental Proliferative Vitreoretinopathy by Retroviral Vector-mediated Transfer of Suicide Gene: Can Proliferative Vitreoretinopathy be a Target of Gene Therapy?

https://doi.org/10.1016/S0161-6420(95)30850-0Get rights and content

Purpose: To determine the potential of somatic gene transfer as a treatment for proliferative vitreoretinopathy (PVR), experimental PVR was induced in rabbits by intraocular injection of fibroblasts bearing the herpes simplex virus thymidine kinase (HStk) gene. These transduced cells should be susceptible to cytotoxicity by exposure to ganciclovir (GCV).

Materials and Methods: Rabbit fibroblasts were transduced with retroviral vectors bearing an HStk gene. Proliferative vitreoretinopathy was induced by injection of 5 × 104 normal or HStk gene-transduced fibroblasts (HStk fibroblasts) into rabbit eyes. Ganciclovir (100 µg per eye) or saline was injected into the vitreous on days 0 and 4. Experimental animals were divided into three groups: group A received HStk fibroblasts with GCV; group B, normal fibroblasts with GCV; group C, HStk fibroblasts with saline. Proliferative vitreoretinopathy also was induced in several other groups of eyes, some receiving GCV and different proportions of HStk fibroblasts to normal fibroblasts, others receiving only normal fibroblasts and GCV. The eyes were examined by indirect ophthalmoscopy on days 4, 7, 14, and 28, and PVR was classified into six stages (0–5).

Results: Proliferative vitreoretinopathy was induced and progressed over time in each group. On day 28, PVR was most severe in animals in group B (average stage, 4.6) and group C (average stage, 4.4). Proliferative vitreoretinopathy was inhibited in group A (average stage, 1.0). The groups that received mixed injection of HStk fibroblasts and normal fibroblasts had intermediate PVR. Results of histologic study showed no apparent toxic or pathologic reaction in the retinochoroidal tissue of group A animals.

Conclusions: Severity of experimental PVR clearly was reduced by transfer of the HStk gene and administration of GCV. This inhibitory effect also was produced by a combination of 10% HStk fibroblasts and 90% normal fibroblasts, indicating a significant bystander effect. These data suggest the potential of somatic gene therapy for the treatment of PVR.

References (26)

  • WF Anderson

    Human gene therapy

    Science

    (1992)
  • FL Moolten

    Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes. Paradigm for a prospective cancer control strategy

    Cancer Res

    (1986)
  • G Plautz et al.

    Selective elimination of recombinant genes in vivo with a suicide retroviral vector

    New Biol

    (1991)
  • Cited by (60)

    • Channelrhodopsins: Visual regeneration and neural activation by a light switch

      2013, New Biotechnology
      Citation Excerpt :

      This technique involves using a recombinant virus containing the ChR2 gene, which is injected into a specific region on the gene and hence expressed either selectively or broadly, depending on the aim. A multitude of viral vectors, including adenoviruses [26], adenoassociated viruses (AAV) [27], retroviruses [28] and lentiviruses [29,30], have been used experimentally. By using viral vectors, precise cells can be targeted by other means apart from using specific promoters.

    • Proliferative vitreoretinopathy

      2012, Retina Fifth Edition
    • Proliferative Vitreoretinopathy

      2005, Retina: Fourth Edition
    • Posterior Segment Trauma: Open Globe

      2005, Retina: Fourth Edition
    • A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy

      2004, Ophthalmology
      Citation Excerpt :

      Enhancing the specificity of treatment regimens to target the cellular or molecular components of the PVR process is a further potential future strategy. Gene transfer has been demonstrated to reduce experimental PVR29 and could also provide a more targeted approach to clinical disease. Recently, in vivo gene transfer–induced overexpression of an attenuated platelet-derived growth factor receptor has been shown to reduce experimental PVR,30 and such an approach, which combines enhanced specificity with a more prolonged therapeutic effect, is an attractive future option.

    View all citing articles on Scopus

    Supported in part by grants EY02061 and EY03040 from the National Institutes of Health, Bethesda, Maryland. The Department of Ophthalmology is a recipient of an award from Research to Prevent Blindness, Inc, New York, New York, and Dr. Sakamoto is a recipient of a foreign scholarship award from Research to Prevent Blindness and from the Nippon Eye Bank Association, Tokyo, Japan.

    View full text